You are hereMarch 12, 2021
Stem Cell-derived CAR‐Natural Killer Cells
Hematopoietic stem cell (HSC) and induced pluripotent stem cell (iPSC)‐derived natural killer (NK) cells displaying chimeric antigen receptors (CAR) offer great hope for the treatment of seemingly incurable oncological malignancies. Long manufacturing times, the safety of cell sources, and the potential for graft vs. host disease and cytokine release syndrome represent just some of the challenges facing CAR cell‐based therapeutics. In a recent STEM CELLS Translational Medicine article, researchers led by Jonathan Arias (Karolinska Institutet, Stockholm, Sweden/Bright SA, Luxembourg) provide compelling evidence for the use of NK cell therapeutics as a reliable off‐the‐shelf option and highlight how the directed differentiation of iPSCs toward HSC and NK cells will address industrial scalability and safety.